Lucia E. Rameh

This study shows that reducing ITPK1 and IPMK activities lowers IP5 levels, which shortens mTORC1 signaling and hinders β-cell metabolic adaptation to high glucose.

This study designs, synthesizes, and characterizes a new class of IPMK kinase inhibitors, showing reduced glioblastoma cell growth and a novel InsP5 metabolic signature.

This study shows multiple inositol phosphate species enhance mTOR and mTORC1 kinase activity in vitro by stabilizing an active form of the kinase.

This study shows IPMK regulates HDAC3 activity and histone H4 acetylation in human cells through inositol phosphate production.